A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway

Published:2020-09 Issue: Volume:18 Page:137-148
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Wei Liuya,Yang Yang,Gupta Pranav,Wang Aihong,Zhao Min,Zhao Yao,Qu Mei,Ke Yu,Liu Ying,Liu Hong-Min,Xu Xin,Sun Yanli,Chen Zhe-Sheng,Hu Zhenbo

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference42 articles.

1. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining;Rowley;Nature,1973

2. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate;Schuster;Blood,2003

3. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia;Bartram;Nature,1983

4. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products;Lugo;Science,1990

5. JAK-STAT signaling activated by Abl oncogenes;Danial;Oncogene,2000

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nilotinib Exerts a Therapeutic Approach via JAK/STAT Pathway and Cytokine Network in Chronic Myeloid Leukemia Cells;Ege Tıp Dergisi;2024-03-19

2. Development of covalent inhibitors: Principle, design, and application in cancer;MedComm – Oncology;2023-10-31

3. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical;Molecules;2023-06-09

4. I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition;Frontiers in Pharmacology;2023-04-12

5. Design, Synthesis, Biological Evaluation, and Preliminary Mechanistic Study of a Novel Mitochondrial-Targeted Xanthone;Molecules;2023-01-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3